Following Germany pharmaceutical firm Bayer’s acquisition of major Merck assets, reports say Bayer will keep several popular brands to the disappointment of several suitors that were looking to snatch up the businesses.
Reports say Bayer will maintain the Dr. Scholl’s and Coppertone brands following the $14 billion buyout of US-based Merck assets. Unnamed sources told reporters that several rivals had looked to acquire the brands, which did not seem to fit in with Bayer’s strictly pharmaceutical portfolio.
But Bayer plans to keep the companies, leading the company to broaden its healthcare businesses into consumer goods.
According to reports, Dr. School’s and Coppertone are each worth about $1 billion. They were part of the acquisition finalized last May following a bidding war with Reckitt Benckiser, Procter & Gamble and Novartis, according to reports.
Full content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
EU Extends Support for Farms and Fisheries Amid Market Disruptions
May 5, 2024 by
CPI
Sony and Apollo Bid $26 Billion for Paramount Acquisition
May 5, 2024 by
CPI
Goldman Sachs Resolves Decade-Old Metal-Rigging Class Action Lawsuit
May 5, 2024 by
CPI
Italian Antitrust Ruling Puts Halt on Intesa Sanpaolo’s Fintech Ambitions
May 5, 2024 by
CPI
Google Antitrust Case: Closing Arguments Conclude
May 5, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI